Herbalife Delivers Fourth Quarter and Full-Year Net Sales Growth, Net Sales and Adjusted EBITDA 1 Exceed Guidance Cristiano Ronaldo Invests $7.5 Million in Herbalife's Pro2col Technology

Fourth Quarter and Full-Year Net Sales Growth,

Net Sales and Adjusted EBITDA1

Cristiano Ronaldo Invests

$7.5 Million in Herbalife's Pro2col Technology

LOS ANGELES, February 18, 2026 - Herbalife Ltd. (NYSE:

HLF) today reported financial results for the fourth quarter and year ended December 31, 2025:

Management Commentary

Herbalife reported fourth quarter 2025 net sales of $1.3 billion, up

6.3% year-over-year, including 80 basis points of FX tailwinds. On a constant currency basis2, net sales increased 5.5% year-over-year

Gross profit margin was 77.5% in the fourth quarter, compared to 77.8%

in the prior year period. On a year-over-year and approximate basis, the change primarily reflects 100 basis points of FX headwinds, 30

basis points of unfavorable sales mix, and 30 basis points of input cost inflation, driven mainly by lower absorption rates. These impacts

were partially offset by 80 basis points of pricing benefits, 10 basis points of lower outbound freight costs, and 30 basis points of

other favorable cost changes.

For the quarter, net income attributable to Herbalife was $85.4 million,

with net income margin of 6.7%, and adjusted net income1 of $47.5 million. Adjusted EBITDA1 of $156.1 million includes

approximately $12 million of FX headwinds year-over-year, with adjusted EBITDA1 margin of 12.2%, down 20 basis points versus

the fourth quarter of 2024. Diluted EPS was $0.81, with adjusted diluted EPS1 of $0.45, which includes a $0.07 year-over-year

Full-year 2025 net sales were $5.0 billion, up 0.9% year-over-year,

including 160 basis points of FX headwinds. On a constant currency basis2, net sales increased 2.5% year-over-year.

Full-year 2025 net income attributable to Herbalife was $228.3 million,

with net income margin of 4.5%, and adjusted net income1 of $219.4 million. Adjusted EBITDA1 of $657.6 million includes

approximately $56 million of FX headwinds year-over-year, with adjusted EBITDA1 margin of 13.1%, up 40 basis points versus

2024. Diluted EPS was $2.20, with adjusted diluted EPS1 of $2.12, which includes a $0.39 year-over-year FX headwind.

Net cash provided by operating activities was $98.3 million and $333.3

million for the quarter and year ended December 31, 2025, respectively. Capital expenditures were $18.5 million and $80.4 million for

the fourth quarter and full-year 2025, respectively, and capitalized software as a service ("SaaS") implementation costs were

approximately $9 million and $25 million, respectively.

In accordance with the terms of the Pro2col Health LLC asset purchase

agreement entered into in April 2025, the Company made a contingency payment of $3.0 million during the fourth quarter following the release

of Pro2col Beta 2.0 in the U.S., Canada and Puerto Rico in December 2025. For full-year 2025, total contingency payments related to Pro2col

As of December 31, 2025, the Company's revolving credit facility

was undrawn, compared to $25.0 million outstanding as of September 30, 2025.

"Our results reflect strong operational and financial momentum,"

said Chief Financial Officer John DeSimone. "For the full year, we delivered our second consecutive year of adjusted EBITDA1

and adjusted EBITDA1 margin expansion, generated strong operating cash flows, reduced debt, and ended 2025 with a total leverage

For the fourth quarter, the Company's North America region delivered

its second consecutive quarter of double-digit new distributor growth, up 19% year-over-year, while Latin America achieved its seventh

straight quarter of year-over-year growth, up 6%. While new distributors joining worldwide declined 5% year-over-year, they increased

16% on a two-year stack basis, reflecting sustained multi-year momentum.

In December, the Company hosted a virtual distributor event introducing

the next phase of its strategic beta program for Pro2col, Herbalife's personalized health and wellness operating system. As part

of the event, the Company released Pro2col Beta 2.0, expanding the availability of beta access to distributors and customers in the U.S.,

Canada, and Puerto Rico. The release also included improvements to distributor marketing pages and the coach dashboard, designed to further

enhance the connection and support between distributors and their customers.

The ongoing beta phases are strategically designed to further advance

platform development and innovation by incorporating in-market user insights to inform personalization capabilities, prioritize new features,

and guide the timing and scope of future rollout phases. Building on these learnings, the Company expects to expand beta access to additional

international markets, beginning with select EMEA markets in 2026.

As announced in a separate press release today, in February 2026, global

sports icon Cristiano Ronaldo, acquired a 10% equity interest in Pro2col Software, an indirect wholly-owned subsidiary of Herbalife Ltd.

that holds the Pro2col technology. Ronaldo invested $7.5 million, along with a commitment to provide services and sponsorship rights to

Pro2col Software. This investment underscores Ronaldo's deep personal commitment to health and nutrition, as well as his shared

vision to make personalized nutrition and wellness more accessible globally.

"For more than 45 years, Herbalife's distributor network

has supported millions of customers on their health journeys," said Chief Executive Officer Stephan Gratziani. "Today, we

are building on that legacy-combining science, data, AI, innovation, and community to bring the next generation of personalized

nutrition and wellness to more people around the world. With Cristiano Ronaldo's investment in Pro2col, our 2025 acquisitions, and

continued investments in product and digital innovation, we are strengthening our platform and expanding our global impact."

Fourth Quarter and Full-Year 2025

Regional Net Sales and FX Impact

First Quarter 2026 Guidance

Full-Year 2026 Guidance

Guidance Assumptions

Additional FY 2026 Expectations

Earnings Webcast and Conference Call

Herbalife's senior management team will host an audio webcast

and conference call to discuss its fourth quarter and full-year 2025 financial results on Wednesday, February 18, 2026, at 5:30 p.m. ET

The audio webcast will be available at the following link: https://edge.media-server.com/mmc/p/si6puiij

Participants joining via the conference call may obtain the dial-in

information and personal PIN to access the call by registering at the following link:

Senior management also plans to reference slides during the webcast

and call, which will be available under the Investor Relations section of Herbalife's website at https://ir.herbalife.com, where

financial and other information is posted from time to time. The webcast will also be available at the same website, along with

a replay of the webcast following the completion of the event and for three months thereafter.

About Herbalife Ltd.

Herbalife (NYSE: HLF) is a premier

health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business

opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets

through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace

a healthier, more active lifestyle to live their best life.

For more information, visit https://ir.herbalife.com.

Director, Global Corporate Communications

Vice President, Head of Investor Relations

Forward-Looking Statements

This release contains "forward-looking statements" within

the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state

securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and

objectives of management, including for future operations, capital expenditures, or share repurchases; any statements concerning proposed

new products, services, or developments; any statements regarding future economic conditions or performance; any statements of belief

or expectation; and any statements of assumptions underlying any of the foregoing or other future events. Forward-looking statements may